Skip to main content
TipRanks
Go Ultimate75% OFF

CV Sciences (CVSI) AI Stock Analysis

502 Followers
CVSI

CV Sciences

(Other OTC:CVSI)

Select Model
Rating:41Neutral
Price Target:$0.01â–²(0.00% Upside)
Action:reiterated
Date:11/13/26

The score is held down primarily by weak financial performance (sharp revenue contraction, persistent losses, and negative operating/free cash flow) and a bearish technical backdrop (price below key moving averages with negative MACD). Corporate events add some support via legal-overhang resolution and a small improvement in profitability metrics (positive adjusted EBITDA), but these are not yet enough to offset the broader deterioration. Valuation is difficult to justify on earnings due to the negative P/E and no dividend support.

Positive Factors
Improving operating efficiencyHigher gross margin combined with lower operating expenses indicates that CV Sciences is improving cost discipline despite weaker sales. If sustained, this operating leverage can support profitability, reduce cash burn, and improve the resilience of the PlusCBD business over the next several quarters.
Negative Factors
Sustained revenue contractionThe persistent decline in revenue indicates that CV Sciences is not yet translating its product activity into durable top-line growth. Continued contraction can reduce scale benefits, weaken retailer momentum, and make it harder for fixed operating costs to be absorbed across the business.

CV Sciences (CVSI) vs. SPDR S&P 500 ETF (SPY)

-100%-50%0%50%100%150%200%250%CVSI-64.29%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$2.17M
Dividend Yield
―
Average Volume (3M)
635.13K
Price to Earnings (P/E)
-1.1
Beta (1Y)
0.74
Revenue Growth
-12.88%
EPS Growth
-8.75%
Country
US
Employees
43
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

CV Sciences Business Overview & Revenue Model

Company Description

CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division fo...

How the Company Makes Money

CV Sciences makes money primarily by selling hemp-derived CBD consumer products (most notably under the PlusCBD brand). Revenue is generated through (1) wholesale/retail distribution, where CV Sciences sells products to retailers and distributors who...

CV Sciences Earnings Call Summary

Earnings Call Date:Aug 17, 2026(Q2-2026)|% Change Since:-60.00%|Next Earnings Date:May 16, 2022
Earnings Call SentimentNeutral

The call presented a balanced picture: the company is making meaningful progress on cost reductions, working capital management and product/brand expansion (including a growing non‑cannabinoid line and DTC efforts) and has achieved modest positive operating cash flow. However, material top-line pressure (revenue down 7% QoQ and 17% YoY; unit sales down 15%), widening GAAP net loss ($0.8M) and a low cash balance (~$0.3M) are significant headwinds. Regulatory uncertainty remains an important risk. Overall, positives (cost discipline, product launches, near cash‑flow breakeven) are counterbalanced by substantial revenue and liquidity challenges.

Positive Updates

Revenue Resilience
Generated revenue of $3.0 million in Q2 2026; while down 7% sequentially (from $3.2M) and 17% year-over-year, management emphasized resilience in a constrained operating environment.

Negative Updates

Top-Line Decline and Volume Pressure
Revenue decreased 7% sequentially and 17% year-over-year to $3.0 million, driven primarily by a 15% decline in unit sales—reflecting continued category contraction and competitive pressure.

Company Guidance

Management guided that the company will prioritize scaling and profitable growth by expanding non‑cannabinoid +PlusHLTH product launches and select international expansion via Cultured Foods while continuing strict cost and working‑capital discipline to drive margins and cash flow. Key metrics referenced: Q2 revenue of $3.0M (down 7% sequential, 17% YoY; unit sales down 15%), gross margin 48.6% (48.9% in Q1; 50.9% year‑ago), SG&A $1.7M (down ~7.9% sequential/~10% YoY), adjusted EBITDA loss $0.1M (flat vs Q1), operating loss $0.3M, net loss $0.8M, positive operating cash flow of ~ $20k in Q2 (also positive in Q1), cash ≈ $0.3M, inventory ≈ $4.0M (vs $4.1M year‑end), and convertible note fair value $1.0M after ~ $0.7M of conversions — with an aim to reach sustainable positive operating cash flow and to remain flexible pending regulatory timing changes (potential delay of Nov 12, 2026 provisions to Dec 11, 2026).

CV Sciences Financial Statement Overview

Summary

Fundamentals are pressured: TTM revenue is down sharply (-25.6%) and the company remains unprofitable (TTM net margin ~-15.7%). Cash generation is weak with negative operating cash flow (-$0.17M) and negative free cash flow (-$0.19M). The balance sheet is a relative positive with moderate leverage (debt-to-equity ~0.80), but ongoing losses increase the risk of renewed balance-sheet pressure.

Income Statement

28Negative

Balance Sheet

44Neutral

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Mar 2022
Income Statement
Total Revenue12.52M13.79M15.71M16.00M16.20M20.05M
Gross Profit6.20M6.75M7.17M7.08M5.55M8.62M
EBITDA-1.19M-562.00K-1.86M3.85M-5.73M-14.35M
Net Income-1.72M-958.00K-2.39M3.10M-8.21M-15.55M
Balance Sheet
Total Assets6.43M6.96M7.93M26.35M12.74M18.07M
Cash, Cash Equivalents and Short-Term Investments308.00K278.00K454.00K1.32M611.00K1.38M
Total Debt891.00K1.61M779.00K442.00K1.53M922.00K
Total Liabilities4.16M5.49M6.13M23.44M13.51M14.52M
Stockholders Equity2.27M1.47M1.79M2.90M-777.00K3.54M
Cash Flow
Free Cash Flow-189.00K-516.00K-879.00K2.25M-1.89M-7.52M
Operating Cash Flow-170.00K-407.00K-861.00K2.25M-1.89M-7.49M
Investing Cash Flow-19.00K-109.00K-28.00K-156.00K0-35.00K
Financing Cash Flow118.00K337.00K32.00K-1.39M1.12M4.37M

CV Sciences Technical Analysis

Technical Analysis SentimentNegative
Last Price0.01

Price Trends

50DMA0.01Negative
100DMA0.02Negative
200DMA0.03Negative

Market Momentum

MACD-0.00Negative
RSI44.40Neutral
STOCH16.67Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVSI, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 44.40 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CVSI.

CV Sciences Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CVSI against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IXHLIXHL47Neutral$21.96M-2.61-12.40%―-100.00%96.25%
YCBDYCBD43Neutral$4.19M-1.22-34.25%―10.01%95.01%
CVSICVSI41Neutral$2.35M-1.11-100.85%―-12.88%-8.75%
COSMCOSM38Underperform$14.84M-0.22-118.89%―33.82%34.05%
IMCCIMCC37Underperform$813.37K-0.02528.80%―-35.33%-110.11%

* Healthcare Sector Average

Performance Comparison

-100%0%100%200%300%CVSIYCBDCOSMIMCCIXHLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CVSI and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CVSICV Sciences0.01-0.02-64.29%
YCBDCbdmd INc0.37-0.13-25.20%
COSMCosmos Holdings 2.95-9.52-76.35%
IMCCIm Cannabis Corp0.54-40.87-98.71%
IXHLIncannex Healthcare Limited Sponsored ADR1.75-8.21-82.42%

CV Sciences Corporate Events

Business Operations and StrategyFinancial Disclosures

CV Sciences Reports Third-Quarter Revenue and Positive Adjusted EBITDA

Positive
Nov 12, 2026

On November 12, 2026, CV Sciences reported third-quarter revenue of $3.0 million, down from $3.3 million a year earlier and unchanged from the second quarter. Gross margin increased to 50.0%, operating expenses fell 11.6% year over year to $1.6 milli...

Business Operations and StrategyLegal Proceedings

CV Sciences Resolves Legal Dispute, Refocuses on Operations

Positive
Oct 26, 2026

CV Sciences reported that it had initiated an arbitration proceeding on February 12, 2025, against its former legal counsel, a dispute that has now concluded. The company has settled the case, receiving $500,000 and entering into a mutual release of...

Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance

CV Sciences Reports Q2 Results Amid Regulatory Reprieve

Negative
Aug 13, 2026

On August 13, 2026, CV Sciences reported second-quarter 2026 results showing revenue of $3.0 million, down 17.5% from a year earlier, as restrictive federal and state regulations weighed on sales volumes and reduced units sold by 14.9%. Despite the t...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026